PRMA Consulting - Fishawack Health
Cytiva
EVA Air Cargo - 2022

C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Techno Trends

TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.

Pfizer Inc. Discovered Breakthrough Respiratory Syncytial Virus (RSV)

Pfizer Inc, discovered breakthrough respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF for the treatment of lower respiratory tract illness in infants from birth up to age of six months by active immunisation of pregnant women. Once approved, the vaccine has the potential...

First-of-its-Kind SOBA-AD, Blood Test Developed to Detect Alzheimer’s Disease

AltPep Corporation developed first-of-its-kind SOBA-AD assay, a simple blood test for the detection of Alzheimer’s Disease. SOBA-AD assay is a blood test conducted to detect toxic oligomers which triggers rapid events associated with AD, such as cognitive impairment...

Breakthrough Monarch eTNS System® Discovered for Drug-Resistant Epilepsy (DRE)

NeuroSigma, discovered breakthrough Monarch eTNS System® Drug-Resistant Epilepsy (DRE). Monarch eTNS System® is designed for individuals with 18 years of age or older to lower the frequency of seizures diagnosed with epilepsy specified by partial-onset seizures, with or without secondary generalization, that are refractory to two or more antiepileptic medications....

Novel Mavacamten Discovered to Treat Obstructive Hypertrophic Cardiomyopathy (oHCM)

LianBio, discovered novel Mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin which is under investigation for the treatment of excessive cardiac contractility. It lowers the risk of cardiac muscle contractility by restricting...

First-of-its-Kind Digital Therapeutic BNT200 Discovered

Blue Note Therapeutics discovered first-of-its-kind prescription-only digital therapeutic BNT200 for the treatment of anxiety and depressive symptoms in adults patients with acute myeloid leukemia (AML) hospitalised for a regimen of high-intensity induction chemotherapy. BNT200 is a software as a medical device (SaMD) designed t0 treat anxiety and depressive...

Breakthrough CardiAMP Cell Therapy System Discovered for Heart Failure

BioCardia®, Inc discovered breakthrough CardiAMP® Cell Therapy System for the treatment of heart failure. CardiAMP Cell Therapy makes use of patients own bone marrow cells delivered to the heart in a minimally invasive, catheter-based procedure. It uses pre-procedural screening assay...

Novel Patho-Seq Assay Discovered for the Detection of Bacteria

Pathogenomix Inc, discovered novel Patho-Seq assay. Patho-Seq uses Next Generation Sequencing for the rapid identifaction of bacteria presented in human sample through dangerous and life-threatening infections. Patho-Seq detects hundreds of clinically relevant bacteria collected from wide...

Telisotuzumab Vedotin (Teliso-V) Developed for the Treatment of Non-Small Cell Lung Cancer

AbbVie developed Telisotuzumab Vedotin (Teliso-V) an investigational antibody-drug conjugate (ADC), to treat patients with non-small cell lung cancer (NSCLC). (Teliso-V) is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) consisting...

New Patritumab Deruxtecan (HER3-DXd) Discovered for the Treatment of Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo discovered new patritumab deruxtecan to treat patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC). Patritumab deruxtecan (HER3-DXd), is the firt irst-in-class HER3 directed antibody drug conjugate (ADC), applicable with third-generation tyrosine kinase inhibitor...

Novel ZetaMet™ Technology Discovered for Metastatic Bone Cancers

Zetagen Therapeutics, discovered novel ZetaMet™ technology for the treatment of metastatic bone cancers. This technology is the first to suspend cancer inhibit pain, and regenerate bone. ZetaMet™ technology was earlier known as ZetaFuse. It is a synthetic, small-molecule, inductive biologic technology introduced to target and resolve metastatic...

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Catalent - Clinical Supply Solutions MasterControl - Choose the Modern Manufacturing Software That’s Right for You Biologics Manufacturing Korea 2022 Medical Fair Asia 2022 Medical Manufacturing Asia 2022